Since target antigen loss is a significant challenge associated with CAR cell therapy, the use of STING agonists in combination could prevent this tumor escape mechanism.[86] A preclinical study using different CAR‐T cells (anti‐CD19‐, anti‐gp75, and anti‐PSMA CAR‐T cells) alongside IT administration of 2′3’ cGAMP demonstrated increased CAR‐T cell killing, resulting in improved overall survival and reduced tumor volume in a melanoma mouse model. This evidence concerns the gene CD19 and neoplasm.